Get the Stockscreener App
563.16
2.53%
13.88
Regeneron Pharmaceuticals Inc stock is traded at $563.16, with a volume of 827.62K.
It is up +2.53% in the last 24 hours and down -16.99% over the past month.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$549.28
Open:
$548.07
24h Volume:
827.62K
Relative Volume:
0.88
Market Cap:
$62.43B
Revenue:
$14.20B
Net Income/Loss:
$4.41B
P/E Ratio:
14.71
EPS:
38.28
Net Cash Flow:
$3.54B
1W Performance:
+3.07%
1M Performance:
-16.99%
6M Performance:
-43.58%
1Y Performance:
-37.51%
1-Day Range:
$545.00
$564.21
1-Week Range:
$533.26
$575.20
52-Week Range:
$525.99
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
The Goldman Sachs Group Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $917.00 - MarketBeat
1,215 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Canada Post Corp Registered Pension Plan - MarketBeat
Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD - Yahoo Finance
Regeneron, Sanofi announce FDA approval of Dupixent for CSU - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $547.00 by Analysts at Bank of America - MarketBeat
Canaccord Genuity Group Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $150.00 - MarketBeat
GKV Capital Management Co. Inc. Purchases Shares of 3,835 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Evergreen Capital Management LLC Acquires 3,030 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Marshall Wace LLP Has $90.75 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Savvy Advisors Inc. Purchases New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
ExodusPoint Capital Management LP Sells 7,047 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition - Reuters
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application | REGN Stock News - GuruFocus
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application - The Manila Times
FDA Decision: EYLEA HD Extended Dosing Rejected But Current 16-Week Regimen Stays Approved - Stock Titan
Rockefeller Capital Management L.P. Sells 3,260 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Dupixent Approved In US As First New Targeted Therapy In Over Decade For Chronic Spontaneous Urticaria - marketscreener.com
Seven Up For Sanofi and Regeneron With Dupixent CSU Approval - insights.citeline.com
Regeneron (REGN) Secures FDA Priority Review for EYLEA HD Injection | REGN Stock News - GuruFocus
FDA Approves Dupixent for Chronic Spontaneous Urticaria Treatment: Regeneron (REGN) | REGN Stock News - GuruFocus
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) - The Manila Times
Press Release: Dupixent approved in the US as the first new - GlobeNewswire
Breakthrough: FDA Clears Dupixent for 300,000 Chronic Urticaria Patients After Decade-Long Wait - Stock Titan
Aware Super Pty Ltd as trustee of Aware Super Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sagespring Wealth Partners LLC Purchases Shares of 536 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
Taurus Asset Management LLC Buys 1,130 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion - Benzinga
FDA to review Regeneron’s sBLA for aflibercept injection 8mg - Yahoo Finance
Regeneron (REGN) Awaits FDA Decision on Eylea HD Expansion - GuruFocus
Regeneron says Eylea HD under FDA review for label expansion - Seeking Alpha
Biocon Biologics deal for Yesafili commercialization - The Pharma Letter
Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts - Benzinga
Regeneron Says Application for Expanded Use of Eylea Accepted for FDA Priority Review - marketscreener.com
Regeneron announces FDA accepted Priority Review sBLA for EYELEA HD - TipRanks
Regeneron (REGN) Advances with Priority Review for EYLEA HD by FDA | REGN Stock News - GuruFocus
Regeneron (REGN) Faces Price Target Cut Amid Conservative Growth Prospects | REGN Stock News - GuruFocus
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indicatio - GuruFocus
FDA reviews new EYLEA HD injection for less frequent dosing - Investing.com
Regeneron Announces FDA Acceptance of Priority Review for EYLEA HD® Supplemental Application for Retinal Vein Occlusion Treatment - Nasdaq
Dodge & Cox Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Guggenheim Capital LLC - MarketBeat
Jump Financial LLC Buys 17,586 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Eylea Hd® (Aflibercept) Injection 8 Mg Sbla Accepted For FDA Priority Review - MarketScreener
EYLEA HD's Breakthrough RVO Treatment Could Cut Injection Frequency by 50% as FDA Grants Priority Review - Stock Titan
Regeneron (REGN) Target Price Cut by BofA Amid Earnings Concerns | REGN Stock News - GuruFocus
XTX Topco Ltd Buys 1,274 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Coign Capital Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron's (REGN) Odronextamab Gains FDA Orphan Designation for Rare Lymphoma Treatment | REGN Stock News - GuruFocus
ANGPTL3 Inhibitor Market Set for Robust Growth During the Forecast Period (2025-2034) Across 7MM Owing to the Rising Demand for Novel Lipid-Lowering Therapies | DelveInsight - Yahoo Finance
Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA - Ophthalmology Times
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):